Please login to the form below

Not currently logged in
Email:
Password:

Dr Andrew Mulberg moves from FDA to Amicus Therapeutics

He becomes vice president of regulatory strategy

Amicus Therapeutics Dr Andrew MulbergUS biotechnology firm Amicus Therapeutics has appointed Dr Andrew Mulberg as its vice president of regulatory strategy.

Serving as a member of Amicus' executive team, Dr Mulberg will be responsible for overseeing the global regulatory strategies for all of the company's rare disease therapy programmes.

He joins Amicus from the US Food and Drug Administration (FDA), where he most recently served as deputy director of the division of gastroenterology and inborn errors products.

Prior to this, Dr Mulberg worked at Johnson & Johnson's pharmaceutical research and development division, serving as the portfolio leader for internal medicine and established products.

Dr Mulberg is a pediatric gastroenterologist, and was attending physician and fellowship director in gastroenterology and hepatology for The Children's Hospital of Philadelphia between 1993 and 2001.

He is currently the board chairman and member of the medical advisory and research committees for the Go4theGoal Foundation, a pediatric cancer foundation.

Dr Jay Barth, chief medical officer at Amicus, said: “I am very pleased to welcome Andrew to our team.

“As we advance several programmes through global clinical development, his direct experience at the FDA within the gastroenterology and inborn errors division, as well as his successful track record in drug development and regulatory approvals within industry, will be very valuable for Amicus.

“Andrew will be instrumental in shaping our regulatory strategies from investigational new drug, or IND, applications and first-in-man studies through regulatory approvals.”

15th July 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics